IP Library Granted Patent US 9,506,931
Granted Patent B2
US 9,506,931 · App. 14/669,923 · Granted Nov 29, 2016

Method for measuring analyte transport across cell membranes using X-ray fluorescence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,506,931
App. No.
14/669,923
Granted
Nov 29, 2016
Kind
B2
Abstract

The present invention includes a method and apparatus for measuring the transport of an analyte through a cell membrane. One or more cells expressing a plurality of ion channels are provided. These cells are loaded with the analyte so that the cells contain at least 10 picograms of the analyte within a volume defined by the area of an x-ray excitation beam and a depth of five times the 1/e attenuation depth for at least one characteristic x-ray signal of the analyte as attenuated by water. The unloaded analyte is removed and the amount of the analyte in the cells is measured with x-ray fluorescence.

Claims (15)

1. A method for measuring the transport of an analyte through a cell membrane, comprising the steps of providing one or more cells expressing a plurality of ion channels, loading the one or more cells with an analyte so that the cells comprise at least 10 picograms of the analyte within a volume defined by the area of an x-ray excitation beam and a depth of five times the 1/e attenuation depth for at least one characteristic x-ray signal of the analyte as attenuated by water, removing the unloaded analyte substantially from the volume, exciting the analyte with a polychromatic x-ray beam, and measuring the x-ray fluorescence of the analyte with an x-ray detector.

2. The method of claim 1 , further comprising unloading the cells and measuring the analyte after it is unloaded from the cells.

3. The method of claim 1 , further comprising lysing the cells prior to measuring the x-ray fluorescence.

4. The method of claim 1 , further comprising reducing matrix of the cells prior to measuring the x-ray fluorescence.

5. The method of claim 1 , further comprising drying the cells prior to measuring the x-ray fluorescence.

6. The method of claim 1 , wherein prior to loading the cells with the analyte, the analyte is substantially depleted in the volume defined by the area of the x-ray fluorescence excitation beam that is incident on the cells and a depth of five times the lie depth for at least one characteristic signal of the analyte in water.

7. The method of claim 1 , wherein the analyte comprises an element having an atomic number greater than 10.

8. The method of claim 1 , wherein the analyte comprises a chemical element selected from the group consisting of zinc, cadmium, thallium, sodium, potassium, rubidium, cesium, magnesium, calcium, barium, strontium, chlorine, bromine, and iodine.

9. The method of claim 1 , wherein the cells are retained in a chamber and wherein at least one portion of the chamber is translucent or transparent to x-rays.

10. The method of claim 9 , wherein the portion of the chamber that is translucent to x-rays passes at least 0.1% of the highest energy x-ray fluorescence signal that are emitted by the portion of the analyte that is located within 1 micron of the x-ray translucent location and that are normal to the x-ray translucent location and incident upon the x-ray translucent location.

11. The method of claim 1 , wherein the cells are immobilized such that a quantity of cells equivalent to at least 1% of the cells which are in the beam path of x-ray fluorescence excitation beam at the beginning of an x-ray fluorescence measurement are retained in the beam path of x-ray fluorescence excitation beam for a period of time which is greater than the measurement time of the x-ray fluorescence measurement.

12. The method of claim 1 , wherein the cells are immobilized such that a quantity of cells equivalent to at least 1% of the cells which are in the beam path of x-ray fluorescence excitation beam at the beginning of an x-ray fluorescence measurement are retained in the beam path of x-ray fluorescence excitation beam for at least 10 seconds.

13. The method of claim 1 , wherein the cells are retained in a chamber, and the orientation of the chamber and the x-ray excitation beam and the x-ray detector allows at least a portion of the population of cells to occupy the volume defined by the intersection of the x-ray excitation beam path and the viewable volume of the x-ray detector.

14. The method of claim 13 , wherein the portion of the population of cells comprises at least 100 picograms of the analyte occupying the volume defined by the intersection of the x-ray excitation beam path and the viewable volume of the x-ray detector.

15. The method of claim 14 , wherein the portion of the population of cells comprising at least 100 picograms of the analyte to occupy the volume defined by the intersection of the x-ray excitation beam path and the viewable volume of the x-ray detector, any barrier between the cells and the x-ray fluorescence detector attenuates the portion of the highest energy x-ray fluorescence signal and that is emitted normal to the barrier by the analyte that is located within 5 microns of the barrier by less than about 99.9% or allows at least 0.1% of the highest energy x-ray fluorescence signal from analyte to pass.

Assignments (14)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2020
From: ICAGEN, INC.; ICAGEN CORP.; XRPRO SCIENCES, INC.; CALDERA DISCOVERY, INC.
To: ADJACENT ACQUISITION CO., LLC
Reel/Frame 053333/0333 →
CHANGE OF NAME Recorded Jul 28, 2020
From: ADJACENT ACQUISITION CO., LLC
To: ICAGEN, LLC
Reel/Frame 053337/0906 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 052304/0304 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 052304/0712 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 047046/0311 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 047046/0214 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047317/0860 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047016/0859 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; ICAGEN-T, INC.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042378/0935 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042379/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2016
From: BIRNBAUM, EVA R.; MILLER, REBECCA L.E.; PETERSON, LORI J.; BERGER, JENNIFER A.; WARNER, BENJAMIN P.
To: CALDERA PHARMACEUTICAIS, INC.
Reel/Frame 037613/0414 →
CHANGE OF NAME Recorded Jan 28, 2016
From: XRPRO SCIENCES, INC.
To: ICAGEN, INC.
Reel/Frame 037638/0543 →
CHANGE OF NAME Recorded Jan 28, 2016
From: CALDERA PHARMACEUTICALS, INC.
To: XRPRO SCIENCES, INC.
Reel/Frame 037688/0708 →
CHANGE OF NAME Recorded Jan 28, 2016
From: CALDERA PHARMACEUTICALS. INC
To: XRPRO SCIENCES, INC.
Reel/Frame 037688/0745 →